Enopace Biomedical is developing a device to treat patients with heart failure. The company's technology comprises a minimally invasive, implantable neurostimulation device designed to increase cardiac efficiency by reducing left-ventricular workload.
The company's Harmony™ System was designed for heart failure patients and is a minimally invasive neuromodulation implant supplies precise and personalized aortic stimulation, while the wearable unit allows the user to switch the therapy on or off, as needed. The Harmony System can be implanted in 30 minutes in a standard catheterization procedure, without the need for general anesthesia.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Enopace Biomedical Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Nov 20, 2017
www.prnewswire.com
Enopace Biomedical Voted # 1 Medical Innovation Company
#Customers
Nov 5, 2015
www.prnewswire.com
World's First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure
#Customers
Jul 15, 2013
www.implantable-device.com
Enopace Biomedical
#Investment
Feb 28, 2013
www.globes.co.il
Enopace Biomedical raises $13m
#Investment
Oct 20, 2011
www.massdevice.com
Sorin invests $7 million in Enopace Biomedical Acquisitions Roundup